Fig. 4: RAD51 knockdown cells are more sensitive to the PG545/PARPi combinations.
From: PG545 sensitizes ovarian cancer cells to PARP inhibitors through modulation of RAD51-DEK interaction
A Immunoblot analysis of RAD51 expression in NTC control vs shRAD51 knockdown OVCAR5 cells with β-actin as loading control. B, C Heat map from the results of CFAs in OVCAR5 NTC (control) vs. OVCAR5 RAD51 KD cells treated with the indicated concentrations of PG545 alone or in combination with rucaparib and olaparib. D, E CI values across the treatment panel for rucaparib and PG545 and for olaparib and PG545 in NTC vs RAD51 KD OVCAR5 cells, respectively was shown. An average CI of 1 indicates an additive effect, CI < 1 a synergistic effect, and CI > 1 an antagonistic effect.
